COMPOSITIONS AND METHODS FOR TREATMENT OF TYPE VII COLLAGEN DEFICIENCIES

The present invention relates to self-inactivating lentiviral vectors comprising the COL7A1 gene or a functional variant thereof and its use in a method for the treatment of Type VII collagen deficiency, such as dominant dystrophic epidermolysis and recessive dystrophic epidermolysis.

Saved in:
Bibliographic Details
Main Authors MASLOWSKI, John, DAILEY, Vernon, CHAKIATH, Marion, ZHANG, Shyuan, MALYALA, Anna
Format Patent
LanguageEnglish
Published 27.11.2020
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to self-inactivating lentiviral vectors comprising the COL7A1 gene or a functional variant thereof and its use in a method for the treatment of Type VII collagen deficiency, such as dominant dystrophic epidermolysis and recessive dystrophic epidermolysis.
Bibliography:Application Number: SG20201009181Q